Your session is about to expire
← Back to Search
Magnetic Stimulation for Psychosis
N/A
Recruiting
Research Sponsored by Mclean Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age between 18-55 years
Diagnosis of a psychotic disorder (i.e. schizophrenia or schizoaffective disorder or bipolar disorder type I)
Must not have
History of fainting spells of unknown or undetermined etiology that might constitute seizures
Any progressive (e.g., neurodegenerative) neurological disorder such as multiple sclerosis or Parkinson's disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up eight minutes before tms and one minute after tms on each of the three tms visit days
Summary
This trial tests if magnetic stimulation can improve processing speed in people with psychotic disorders.
Who is the study for?
This trial is for adults aged 18-55 with a psychotic disorder (schizophrenia, schizoaffective disorder, or bipolar I). Participants must be stable outpatients who speak English and can complete study tasks. Exclusions include recent substance use disorders, certain brain conditions, metal implants not MRI-safe, pregnancy, seizure history, and progressive neurological diseases.
What is being tested?
The study tests if magnetic stimulation (iTBS/cTBS) affects cognitive processing speed in psychosis. Participants will do problem-solving tasks and have brain scans before/after transcranial magnetic stimulation (TMS), which temporarily alters brain activity.
What are the potential side effects?
While TMS is generally safe and FDA-approved for some conditions like depression and OCD, potential side effects may include discomfort at the stimulation site, headache, lightheadedness or seizures in very rare cases.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 55 years old.
Select...
I have been diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder type I.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had fainting spells that might be seizures.
Select...
I have a worsening condition like multiple sclerosis or Parkinson's.
Select...
I am experiencing symptoms of high pressure inside my skull.
Select...
I have had a head injury that caused me to lose consciousness for more than 15 minutes.
Select...
I have a brain condition due to genetics (like Neurofibromatosis) or an event (like a stroke).
Select...
I don't have uncontrolled chronic conditions like heart issues or asthma.
Select...
I have a tumor in my brain.
Select...
I have had multiple seizures or have been diagnosed with epilepsy.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ eight minutes before tms and one minute after tms on each of the three tms visit days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~eight minutes before tms and one minute after tms on each of the three tms visit days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
BACS Digit Sequence test
BACS Symbol Coding test
functional Magnetic Resonance Imaging
Trial Design
3Treatment groups
Active Control
Placebo Group
Group I: continuous theta burst stimulation (cTBS)Active Control1 Intervention
Participants complete MRI scanning and cognitive testing followed by rTMS (cTBS pattern) followed by repeat cognitive testing and MRI scanning
Group II: Intermittent theta burst stimulation (iTBS)Active Control1 Intervention
Participants complete MRI scanning and cognitive testing followed by rTMS (iTBS pattern) followed by repeat cognitive testing and MRI scanning
Group III: sham rTMSPlacebo Group1 Intervention
Participants complete MRI scanning and cognitive testing followed by sham rTMS followed by repeat cognitive testing and MRI scanning
Find a Location
Who is running the clinical trial?
Beth Israel Deaconess Medical CenterOTHER
861 Previous Clinical Trials
12,932,731 Total Patients Enrolled
4 Trials studying Psychosis
174 Patients Enrolled for Psychosis
Mclean HospitalLead Sponsor
217 Previous Clinical Trials
22,098 Total Patients Enrolled
9 Trials studying Psychosis
962 Patients Enrolled for Psychosis